Panion & Bf Biotech Inc. (1760.TW)
TWD 66.2
(0.15%)
TWD 66.2
(0.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 193.2 Million TWD | 968.98% |
| 2022 | 18.07 Million TWD | -91.91% |
| 2021 | 223.45 Million TWD | -75.95% |
| 2020 | 929.21 Million TWD | 466.05% |
| 2019 | -253.84 Million TWD | 57.39% |
| 2018 | -595.68 Million TWD | -168.92% |
| 2017 | -221.51 Million TWD | -17.83% |
| 2016 | -187.99 Million TWD | -47.14% |
| 2015 | -127.76 Million TWD | 22.05% |
| 2014 | -163.9 Million TWD | -10.48% |
| 2013 | -148.35 Million TWD | -155.74% |
| 2012 | 266.16 Million TWD | 0.19% |
| 2011 | 265.66 Million TWD | 36.73% |
| 2010 | 194.29 Million TWD | 157.3% |
| 2009 | 75.51 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 163.99 Million TWD | -21.94% |
| 2024 Q1 | 210.09 Million TWD | 8.74% |
| 2023 FY | 193.2 Million TWD | 968.98% |
| 2023 Q4 | 193.2 Million TWD | -42.12% |
| 2023 Q1 | 107.65 Million TWD | 495.65% |
| 2023 Q3 | 333.79 Million TWD | 338.5% |
| 2023 Q2 | 76.12 Million TWD | -29.29% |
| 2022 Q2 | 44.87 Million TWD | -76.46% |
| 2022 Q4 | 18.07 Million TWD | -81.76% |
| 2022 Q1 | 190.6 Million TWD | -14.7% |
| 2022 FY | 18.07 Million TWD | -91.91% |
| 2022 Q3 | 99.11 Million TWD | 120.89% |
| 2021 Q2 | 861.1 Million TWD | -8.33% |
| 2021 Q3 | 237.15 Million TWD | -72.46% |
| 2021 Q4 | 223.45 Million TWD | -5.78% |
| 2021 FY | 223.45 Million TWD | -75.95% |
| 2021 Q1 | 939.38 Million TWD | 1.09% |
| 2020 Q3 | -20.83 Million TWD | 89.6% |
| 2020 Q2 | -200.28 Million TWD | 9.06% |
| 2020 Q1 | -220.22 Million TWD | 13.24% |
| 2020 Q4 | 929.21 Million TWD | 4559.66% |
| 2020 FY | 929.21 Million TWD | 466.05% |
| 2019 Q2 | -386.91 Million TWD | 25.16% |
| 2019 FY | -253.84 Million TWD | 57.39% |
| 2019 Q3 | -208.72 Million TWD | 46.05% |
| 2019 Q4 | -253.84 Million TWD | -21.62% |
| 2019 Q1 | -516.97 Million TWD | 13.21% |
| 2018 Q3 | -550.16 Million TWD | 23.99% |
| 2018 FY | -595.68 Million TWD | -168.92% |
| 2018 Q4 | -595.68 Million TWD | -8.28% |
| 2018 Q2 | -723.76 Million TWD | 0.18% |
| 2018 Q1 | -725.05 Million TWD | -227.32% |
| 2017 Q4 | -221.51 Million TWD | -13.55% |
| 2017 FY | -221.51 Million TWD | -17.83% |
| 2017 Q3 | -195.08 Million TWD | 20.87% |
| 2017 Q2 | -246.52 Million TWD | -231.13% |
| 2017 Q1 | 187.99 Million TWD | 200.0% |
| 2016 Q1 | -107.76 Million TWD | 15.65% |
| 2016 Q2 | -107.76 Million TWD | 0.0% |
| 2016 Q4 | -187.99 Million TWD | 0.0% |
| 2016 FY | -187.99 Million TWD | -47.14% |
| 2015 Q1 | -159.98 Million TWD | 2.39% |
| 2015 FY | -127.76 Million TWD | 22.05% |
| 2015 Q2 | -159.98 Million TWD | 0.0% |
| 2015 Q4 | -127.76 Million TWD | 0.0% |
| 2015 Q3 | -127.76 Million TWD | 20.14% |
| 2014 Q1 | -193.23 Million TWD | -30.26% |
| 2014 Q2 | -190.72 Million TWD | 1.3% |
| 2014 FY | -163.9 Million TWD | -10.48% |
| 2014 Q4 | -163.9 Million TWD | 0.66% |
| 2014 Q3 | -164.98 Million TWD | 13.5% |
| 2013 Q1 | 287.77 Million TWD | 8.12% |
| 2013 Q2 | 285.22 Million TWD | -0.89% |
| 2013 Q3 | -148.35 Million TWD | -152.01% |
| 2013 Q4 | -148.35 Million TWD | 0.0% |
| 2013 FY | -148.35 Million TWD | -155.74% |
| 2012 Q2 | 281.89 Million TWD | 0.0% |
| 2012 Q3 | -73.15 Million TWD | -125.95% |
| 2012 FY | 266.16 Million TWD | 0.19% |
| 2012 Q4 | 266.16 Million TWD | 463.85% |
| 2011 Q2 | 247.02 Million TWD | 0.0% |
| 2011 FY | 265.66 Million TWD | 36.73% |
| 2011 Q4 | 265.66 Million TWD | 0.0% |
| 2010 Q4 | 194.29 Million TWD | 0.0% |
| 2010 FY | 194.29 Million TWD | 157.3% |
| 2009 FY | 75.51 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 196.021% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 77.806% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 79.436% |
| GenMont Biotech Incorporation | 2.71 Million TWD | -7024.189% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 146.466% |
| Adimmune Corporation | 685.12 Million TWD | 71.8% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 85.699% |
| Polaris Group | -2.41 Billion TWD | 107.987% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 178.346% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | -254.966% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -3858.369% |